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A B S T R A C T
Focusing on the case of time-lapse imaging (TLI), this paper analyses how medical professionals negotiate the use
of new ‘add-on’ fertility treatments in light of the limited evidence available. The data produced by TLI tech-
nologies is meant to help professionals identify the best embryo to be implanted. Embryo selection is essential in
IVF practice for increasing pregnancy rates and reducing the negative effects of repeated failures. More than 5
years after the introduction of TLI in IVF labs, however, there has been no conclusive randomised control trial
(RCT) evidence to show that the tools do indeed have a significant impact on pregnancy rates. Nonetheless,
many public clinics in the UK have adopted such technologies. Consequently, our research asks: How is the use of
TLI tools legitimised by professionals, in light of contradictory evidence? Focusing on 25 semi-structured staff
interviews, we argue that professionals use several strategies to legitimise the use of TLI in the clinic without,
however, challenging the tenets of evidence-based medicine (EBM) and the value it places on RCTs. Rather,
professionals emphasise various advantages that TLI offers, including its use as a lab tool, its potential for
knowledge production in embryology, and the role it plays in the management of patient expectations and
course of treatment. This paper contributes to debates on the role of EBM in modern medicine and fertility care
specifically – an area where this inter-relationship has been underexplored. We conclude by suggesting avenues
towards a more nuanced understanding of EBM as it relates to IVF treatment and a rapidly changing bio-
technology context.
1. Introduction
Since the birth of the first IVF baby in 1978, the number of children
conceived through assisted reproductive technology worldwide has
reached over 6 million. Nevertheless, IVF success rates remain quite low
overall. For instance, the UK live birth rate (LBR) was 22% in 2017
(HFEA, 2019a). To increase success rates, countless adjuvant therapies
and techniques have been introduced in the last few decades. These are
referred to as ‘add-ons’. A recent survey conducted by UK regulator, the
Human Fertilisation and Embryology Authority (HFEA), shows that
over 70% of patients have had one or more add-ons included in their
fertility treatment (HFEA, 2018).
Recently, the efficacy of add-ons has been criticised in the medical
literature as lacking robust evidence (Heneghan et al., 2016) and for
offering little or poor‐quality information to patients (Spencer et al.,
2016). In the UK, subsequent spin-off media responses, including a BBC
Panorama documentary (The Fertility Business, 28 November 2016),
claimed that the wide use of over 30 add-ons, usually offered at a
charge, was aimed solely at increasing clinic profits. The UK fertility
sector has been criticised for making ‘false claims of effectiveness to
take financial advantage of desperate couples’ (Rutherford, 2017, p.
1850).
Although add-on treatments are widely used in most NHS (public)
clinics, debates have focused on commercialisation and additional costs
charged by private clinics. Despite treating a mix of privately- and
publicly-funded patients, NHS clinics usually do not charge extra for
add-on treatments. With limited commercial interests, however, the
public fertility sector suffers from a lack of funding, especially in
England, where only 35% of IVF cycles are publicly-funded (HFEA,
2019a). Interestingly, criticism of the inclusion of add-ons in state care
regimes has been marginal, compared to other treatments lacking de-
cisive efficiency evidence, such as homeopathy, for example (Hansen
and Kappel, 2012). Currently, there is little information on the use of
add-ons in public clinics, despite the above-mentioned controversy.
To explore how NHS fertility professionals legitimise the use of add-
ons in their medical practice, we investigate the case of one of the most
diffused add-ons: time-lapse imaging (TLI). TLI tools are laboratory
incubators with integrated cameras that take recurrent pictures of
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embryos during their first days of development. Although TLI has
several potential benefits (constant embryo monitoring, quality control,
teaching applications), such tools were initially marketed as able to
increase pregnancy rates, entering clinical practice with the aim of
improving patient outcomes. Nonetheless, two recent Cochrane reviews
concluded that there is insufficient evidence of increases in LBRs to
justify the use of TLI over conventional incubation (Armstrong et al.,
2015, 2019).
The aim of this article is not to take sides in the debate on public
funding of TLI. Rather, the intention is to analyse how TLI legitimacy
emerges in the IVF professional discourse. Focusing on the analysis of
interview data collected in 5 NHS centres in the UK, we will present the
strategies that NHS-based professionals use to legitimise their routine
use of TLI in their medical practice. We argue in this article that IVF
professionals share orthodox views on notions of acceptable evidence,
while simultaneously offering alternative perspectives on the role of TLI
in improving clinical practice. Their negotiation of legitimacy focuses
on three main strategies: presenting TLI as an innovative piece of la-
boratory equipment; highlighting its crucial role in the production of
knowledge; and the ability of these tools to offer additional information
to manage patient hopes and expectations.
2. The hegemony of the orthodox EBM discourse: a critical
overview
The late 20th century saw the diffusion and advancement of evi-
dence-based medicine (EBM) as a response to the lack of standardisa-
tion in medical care and concerns that new research was not used in
routine clinical decisions. Notwithstanding the hegemonic position of
EBM in Western medical discourse, many criticisms have arisen from
the medical community itself (see for instance, Feinstein and Horwitz,
1997; Kristiansen and Mooney, 2004), focusing on the weaknesses of a
generalised evidence base (Kirmayer, 2012), EBM's devaluation of
professional judgement (Feinstein, 1994; Goldenberg, 2006) and pa-
tients' life narratives (Greenhalgh, 2014). Similar critiques have
emerged from the social sciences, where authors have explored EBM
cultural assumptions (De Vries and Lemmens, 2006), professional re-
sistance toward EBM (Armstrong, 2007; Bhandari et al., 2003; Pope,
2003; Traynor, 2009) and its inability to remove professional judge-
ment from clinical decision-making (Kelly and Moore, 2012;
Mykhalovskiy, 2003; Mykhalovskiy and Weir, 2004; Upshur, 2005).
EBM practice has standardised the quality assessment of research
evidence (Goldenberg, 2006; Lambert, 2006), thus creating hierarchies
of evidence in medicine. In the EBM pyramid of evidence (for an
overview see Murad et al., 2016), meta-analyses of randomised con-
trolled trials (RCTs) and RCTs are ranked as top quality evidence, while
non-randomised trials (such as cohort studies and case-control studies),
qualitative, observational, and other small-scale studies are considered
to be of low quality.
RCTs have had a central role in the diffusion of EBM (Devereaux and
Yusuf, 2003). Including procedures such as blinding, randomisation,
and placebo controls, the RCT design has gained dominance in research
methodology for three main reasons: generalisability, causal inference
and perceived non-bias. Although RCTs have significant and well‐-
known limitations (for a summary see Deaton and Cartwright, 2018),
they have gained concrete authority as a method of investigation.
Within medicine, a strict orthodox perspective has emerged where only
good-quality RCTs and meta-analyses are seen as ‘hard evidence’ or the
only acceptable way to establish the effectiveness of drugs and devices
(Feinstein and Horwitz, 1997).
Recent debates on RCTs (see the special issue in this journal edited
by Mowat et al., 2018) have seen reiterations of criticisms of the evi-
dence hierarchy (Concato et al., 2000; Deaton and Cartwright, 2018).
Methodological problems with trials (Timmermans and Berg, 2003) and
meta-analyses (Moreira, 2007) as well as the everyday difficulties of
producing experimental knowledge (Miles et al., 1997) have been
thoroughly explored in the social science literature. Although the lack
of RCTs does not always diminish confidence in therapeutic effective-
ness (Borgerson, 2005), new treatments are often required to meet
standards that many established medical practices have never actually
met (Morreim, 2003).
Empirical studies of EBM enactment in medical practice have shown
that evidence cannot replace professional knowledge and skills (Berg
and Timmermans, 2000; Tonelli, 2006); rather, medical expertise and
evidence are complementary forms of knowledge (Timmermans and
Berg, 2003). Even when professionals do not resist EBM, they still rely
on a variety of knowledge forms (Armstrong, 2002; Latimer et al., 2006;
Rabeharisoa and Bourret, 2009). Similarly, a recent study (Hughes and
Doheny, 2019) investigating Welsh NHS deliberations on high-cost
drug funding, demonstrates how such debates must still consider or-
ganisational and lifeworld factors, not just ‘hard’ evidence.
3. The discourse of evidence in IVF
Over the years, IVF development has been technologically driven
rather than evidence-based. Neither the early experimental procedures
nor the following additional treatments (sperm injection being the
prime example) have been routinely scrutinised through EBM protocols
before their clinical introduction. An excessive enthusiasm for new
technological interventions and their commercialisation has always
been a source of concern in the professional community (Hurley, 2013).
However, the current controversy on add-ons has arisen following BBC
Panorama's request to Oxford University's Centre for Evidence-Based
Medicine for an investigation. The resulting publications (Heneghan
et al., 2016; Spencer et al., 2016) only included the ‘highest level of
evidence’ in their analysis (e.g., Cochrane reviews and non-Cochrane
systematic reviews), concluding that there is no data to suggest that any
add-ons can improve LBRs and criticising the HFEA for not providing
sufficient guidance to patients.
As a response, the HFEA started an independent assessment and in
2017 launched a webpage (HFEA, 2019b) where patients could find
efficiency and safety information on the 9 most widely-used add-ons.
This initiative aimed to improve informed choice ‘without completely
denying patient-access to potentially beneficial innovations’ (Macklon
et al., 2019). However, the HFEA also adopted a conventional EBM
perspective on evidence, which is summarised in a traffic light system:
green light, for treatments with more than one quality RCT; amber
light, for treatments with a small or conflicting body of evidence and
further research required; red light, where no evidence of safety or
effectiveness exists. At the time of writing, none of the add-ons re-
viewed has a green light.
The controversy has generated heated debate in the medical lit-
erature, where professionals argued that, in IVF, ‘appropriately pow-
ered, well-designed, peer-reviewed RCTs, with an LBR outcome mea-
sure which go on to report on child health, are the gold standard of
evidence based medicine’ (Harper et al., 2017, p. 489). Repeated pleas
to conduct more quality RCTs before routinely offering treatments to
patients proliferated in the professional community (Repping, 2019;
Wilkinson et al., 2017). However, as some experts noted (Macklon
et al., 2019), the pursuit of the gold standard has, so far, left profes-
sionals in a difficult position: lacking robust evidence to make clinical
decisions, while being condemned for using unproven treatments.
A major obstacle emerging in evidence production is the criteria
divide between EMB reviewers and IVF professionals (Dhont, 2013),
with the former emphasising LBRs as the outcome, while professionals
focus on pregnancy rates. A second problem is the number of partici-
pants required to demonstrate a clinically- and statistically-significant
impact on LBRs (Stocking et al., 2019), where proving a 5% increase
requires over 2500 patients (Wilkinson et al., 2019). In a few successful
cases, when good quality RCTs were finally published, the treatments
assessed were already obsolete (Macklon et al., 2019). Clinicians have
attempted to circumvent the problem by using routinely collected data
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and large electronic databases. This, however, is not gold standard
evidence due to the lack of random allocation. Finally, the lack of
consistency in data reporting often precludes meta-analyses (Wilkinson
et al., 2019).
TLI is a prime example of the problems related to evidence-pro-
duction: while unanimously being considered safe by the professional
community, no clear consensus exists over its ability to increase LBRs.
Although several RCTs have been conducted, two Cochrane reviews
(Armstrong et al., 2015, 2019) and several non-Cochrane meta-analyses
concluded that available evidence is still insufficient to prefer TLI over
standard incubators. Interestingly, reviewers also critiqued the low
evidence quality (e.g., lack of data on LBRs, inconsistent reporting, poor
blinding and randomisation procedures). Nonetheless, even orthodox
EBM supporters suggest that TLI has further potential benefits that need
to be explored in order to determine what its best role in the IVF la-
boratory is (Harper et al., 2017). Despite the heated debate on add-ons,
the extended social science literature on IVF has overlooked how fer-
tility professionals legitimise their use of treatments in clinical practice.
This paper fills this gap by examining the legitimation narratives en-
acted by professionals and their understanding of evidence.
4. Narrative legitimation in medicine
The discursive legitimation of medical practices is an important tool
that professionals employ in order to justify the use of novel treatments
or technologies. In this article, we focus on a ‘narrative of legitimation’
analytical frame, which has been employed by other empirical studies
of medicine (Baer, 2006; Foley and Faircloth, 2003; Lambert, 2012;
Tausig and Subed, 1997). Authors have explored legitimation in nat-
uropathy (Baer, 2006), midwifery (Foley and Faircloth, 2003) and local
medical and healing knowledge (Lambert, 2012; Tausig and Subed,
1997).
Using the example of midwives' professional legitimation, Foley and
Faircloth (2003, p. 168) argue that discourses are ‘not something con-
veyed in a narrative vacuum,’ but are rather ‘based on the interpretive
wants and needs of the teller.’ As such, medical professionals will in-
voke a certain set of legitimation narratives (Foley and Faircloth, 2003).
In the case of TLI, the three emerging dominant types of legitimation
discourses employed by professionals are embedded in the current
discourse of evidence in IVF.
The question of how professionals legitimise the use of alternative
forms of evidence in their practice has been investigated extensively in
the literature on complementary and alternative medicine (CAM)
(Jackson and Scambler, 2007; Derkatch, 2016; Gibson, 2018). Although
CAM treatments are found worldwide and are offered by many state
care regimes, they have been ostracised by EBM supporters as ‘un-
proven medicine’ (Fontanarosa and Lundberg, 1998). Social studies of
CAM have underlined the epistemological incompatibility between the
orthodox EBM approach and holistic methods focusing on in-
dividualised care (Degele, 2005; Trnka and Stöckelová, 2019).
Borgerson (2005) summarises three possible alternative options for
professionals working towards legitimacy of CAM in the medical com-
munity: accept EBM standards and produce evidence accordingly; rely
on lower evidence to support their decision; critically engage with EBM
and propose alternative standards.
We argue in this article that IVF professionals share orthodox views
on notions of acceptable evidence, while simultaneously offering al-
ternative perspectives on the role of TLI in improving clinical practice.
5. Methodology
Data presented in this article are part of a larger project and were
collected between June 2017 and March 2019. This included ethno-
graphic observations and interviews carried out by both authors in NHS
sites where fertility treatment is provided, including the use of TLI
tools. Clinics were selected based on their frequent use of TLI, avail-
ability, and willingness to participate in the study. Clinics agreed to
participate in the research study and all staff were informed ahead of
time about study procedures. All clinics are located in England. Further
details about location cannot be disclosed due to confidentiality con-
cerns. In addition to university ethics approval, we received research
clearance from the NHS and each clinic site separately.
Although our understanding of local IVF practices is supported by
observations in the clinics, in this article, to explore how the use of TLI
is legitimised by professionals, we focus on data from interviews only.
IVF professionals working in the observation sites were personally ap-
proached by the researchers regarding interviews. Participation was
voluntary and interviewees signed a consent form. We conducted a total
of 25 interviews with NHS staff. A minority of interviewees were not lab
staff, but had knowledge of TLI or had talked to patients about the use
of such tools (for details, see Table 1). Interviews lasted between 45 and
90 min and were audio recorded and professionally transcribed. The
interview guide was designed to obtain participants' experiences with
using TLI, its challenges, benefits, and place in IVF treatment in the UK.
The interviewers carefully elicited professionals’ views on the use of TLI
as an add-on treatment and its evidence, without expressing any per-
sonal opinions on the matter.
Data analysis was carried out in two stages. In the initial stage of
analysis, we entered all observation and interview data into NVivo, a
software package for organising and analysing qualitative data.
Following this, the data were coded both deductively, using themes
derived from previous literature, and inductively, where we assessed
new themes. A potential list of codes was agreed upon in advance. As
new codes appeared, we cross-checked each other's work so as to reach
consensus on the main emerging themes. Analysis of all data involved a
continual process of literature review, coding, and memo writing.
Grounded theory was primarily used to guide the process of analysis,
from coding to developing larger themes (Glaser and Strauss, 2017).
However, discourse analysis principles were also applied in order to
take into account the social context in which the conversation occurred,
including previous conversations and power relationships (Wodak and
Meyer, 2015). We paid close attention to professionals': 1) under-
standing of the purpose of TLI; 2) opinion on the evidence available for
TLI; 3) views on the production of evidence for IVF treatments; 4) views
on technological development in IVF; 5) understanding of the fit of TLI
in their clinic; 6) challenges experienced using TLI; and 7) experiences
with patients who have had TLI included in their treatment.
The second stage of analysis focused on the interviews to examine
the professional legitimation narratives. Using an interpretive practice
and narrative legitimation approach (Gubrium and Holstein, 1997;
Holstein and Gubrium, 2000), we paid attention to professionals' ar-
guments in favour of the use of TLI in fertility clinics. Interpretive
practice can be conceptualised as the way in which respondents con-
struct reality through storytelling (Holstein and Gubrium, 2000). In-
terpretive practice, however, is also related to respondents' context and
the experiences they draw upon to explain their practices. In the case of
TLI, our interviewees drew upon their experience with this technology
and their perception of patients’ needs and wants. The narrative
Table 1
Data collection.
Semi-structured interviews Heads of embryology Senior embryologists Embryologists Clinical director Fertility consultants Research nurses Nurses
25 4 5 9 1 2 2 2
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legitimation approach has allowed us to analyse the data without
making a value judgement on the appropriateness of TLI and its use. It
has also allowed us to highlight professional narratives and how they
legitimise the use of a technology in relation to the dominant discourse
of EBM.
One of the limitations of our sample is that clinics where TLI is
integrated into daily practice were more likely to participate in the
research. We are aware that there are clinics where staff are more re-
sistant to incorporating such technologies into practice. Our access to
participants from such clinics was limited. Out of the 5 clinics where the
research took place, 4 put all or most patient embryos in TLI incubators.
This practice is different from some private clinics where patients pay
an extra fee for the inclusion of TLI in their treatment. However, some
of the professionals interviewed had previous experience of working in
private clinics and talked about this during their interviews.
Nonetheless, our data can only speak for NHS/semi-public clinics where
efforts have been made to incorporate TLI into daily lab practice. That
being said, our understanding is that the integration of TLI technologies
into UK clinics, and particularly NHS ones, is rapidly expanding.
6. Findings
Three main legitimation narratives emerged in our analysis: the lab
usefulness of TLI, its potential for knowledge creation, and its ability to
support patient needs. The strategies that professionals use to legitimise
the use of TLI tools in the lab emphasise technology benefits that are
not necessarily captured by EBM discourses. Nonetheless, these strate-
gies were not a direct critique of the value placed on RCTs by modern
medicine. We found that interviewees did not question the EBM para-
digm. Rather, they agreed that more high-quality evidence is needed,
but were generally hopeful that TLI will prove to be beneficial in
clinical practice.
6.1. Time-lapse as lab tool
TLI is quite different from other add-ons offered in the UK in that it
does not involve any invasive bodily procedures. For example, the en-
dometrial scratch disrupts a woman's endometrium prior to embryo
transfer, while intralipids are administered to the patient intravenously.
Due to their invasive nature, such procedures carry more negative
connotations. TLI technologies, on the other hand, are not meant to
treat infertility, but rather help in the selection of a transfer embryo.
Interestingly, we found that professionals often categorise TLI tools as
lab equipment. This distinctive feature of TLI played an important role
in interviewees' understanding of it, its purpose, and the need for evi-
dence. Most notably, they stressed that the tool has been a positive
change for the lab and its routine. This was seen as an advantage that
could compensate for the lack of conclusive efficiency data. Two em-
bryologists explained the significance of TLI as a lab tool:
But time-lapse has so many other uses, right, for research and knowledge
and understanding everything. And it is convenient and embryologists
don't have to come at 7.30 in the morning and check for fertilisation
because you won't miss fertilisation, that is one of the other things.
Because traditionally, without time-lapse, what we do, we put the sperm
and the eggs together or inject, and the pro-nucleus appears and then it
disappears, so we don't know when it appears but we want to catch it
before it disappears […] But with time-lapse there is no problem. So you
can go back and see from first hour to the 20th hour. (Head of embry-
ology, Clinic D).
Time lapse is a modern way of working. It's like, you know, I'm quite tech
focused so I like going in and being able to look at embryos and see what
they did […] for me I just like when embryos go into time-lapse so you get
to look at them. (Embryologist, Clinic A).
TLI has helped embryologists monitor embryos in a convenient and
efficient way. It has removed the need to take embryos out of the in-
cubator once a day to assess them under the microscope. We observed
that it has also provided comfort to staff that important events such as
nucleation and fertilisation are not missed.
By emphasising its merits as a lab tool, professionals tried to counter
the dominant narrative that TLI is only of value if it can improve LBRs.
Many seemed hopeful, however, that the evidence will come out
eventually and it is just a matter of time before TLI proves its worth
beyond the lab. For most, the routine monitoring benefits were salient
in their evaluation of this new technology. Professional perception of
TLI contrasts with the initial marketing campaigns for such tools –
campaigns that promised dramatic increases in pregnancy rates for
patients. We observed a significant disconnect between the initial
promissory discourses surrounding TLI as ‘treatment’ and the practical
purpose that it serves in IVF labs currently. Professional views showed
ambiguity regarding the purpose of TLI. Consequently the role of evi-
dence also became unclear due to EBM's inability to fully capture the
purpose and multiple uses of TLI.
The ability to practice EBM was also contrasted with the rapid pace
of innovation in the field. Interviewees expressed frustration with the
hope and hype brought about by the launch of new tools and treatments
in IVF. On one hand, they acknowledged the importance of evidence,
but on the other hand, they felt technology is moving too fast in this
ever-changing field of medicine. This conundrum was summed up by
one respondent:
Things are developing so quickly that trying to get a true randomised
control trial seems that you're just putting the clock back because things
are already moving further and further down the line. So we have to deal
in some cases where there is evidence by smaller studies, by whatever else
and have an idea and that will at least, pilot studies will at least put you
in the position to say right, this is more interesting and at least you can
exclude the stuff that doesn't work at that point. (Clinical director, Clinic
B).
Due to the fast pace of technological change in fertility care over the
past few decades, the task of conducting RCTs and waiting for results
was seen as unfeasible by many interviewees. Professionals did value
evidence, but they felt that there are bigger commercial and organisa-
tional forces that dictate the treatments that their clinics decide to offer.
They talked about having to play ‘catch up’ with private clinics who
adopt new technologies more hastily. Professionals felt that the com-
mercial logic of fertility medicine in the UK does not leave much room
for regulation informed by evidence. Nevertheless, TLI is a technology
that interviewees felt positively about, especially in light of its practical
uses in the lab.
The conceptualisation and legitimation of TLI as a lab technology
lent itself to another advantage: the knowledge that this add-on does no
harm to the patient or their embryos. Consequently, the need for evi-
dence seemed slightly less urgent than in the case of invasive proce-
dures. Professionals were not naïve regarding the yet unproven status of
TLI as an efficient add-on. However, they stressed that, in theory, un-
interrupted culture must be better for embryos as they are not exposed
to potentially damaging outside conditions. This, in turn, downplayed
the immediate need for evidence. For example, one interviewee ela-
borated on the relationship between harm and evidence:
Even if you tell them [patients] that there's no evidence, they may think
okay, there is no evidence that it helps but there is definite evidence that it
doesn't do any harm. In which case they go for that aspect. If you tell
them that putting embryos in time lapse will harm the embryos they will
definitely say I don't want to do it. But if you tell them that we don't know
whether it helps or not, you may try it if you want to, and then they'll say
okay, fine, there is no harm at least. (Fertility consultant#1, Clinic D).
When the possibility to practice EBM was constrained, professionals
looked for alternative ways to judge a new technology and decide
whether or not it should be offered to patients. In the case of TLI, some
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of its intrinsic features, such as its uses as a lab tool and very low harm
potential, worked to its advantage and timely adoption.
6.2. Potential for knowledge production
Evaluating TLI only in terms of efficiency would not capture its
potential for knowledge production, according to many of our inter-
viewees. Professionals highlighted the complexities of embryo devel-
opment and the importance of additional information made available to
embryologists by TLI technologies. A salient benefit was the ability to
deselect embryos that behave abnormally. Abnormal events would be
harder to observe without TLI because the embryos would not be
monitored 24/7. An embryologist explains:
I'd still preferentially use it because I think there is enough evidence to say
like we said before about the direct cleavage embryos and you've got a
much better time frame to see fertilisation results. We sometimes see, you
know, we've put an embryo in and called it normally fertilised, it's got two
PNs [pronuclei], and then a couple of hours later a third PN pops up and
you'd never in a static observation, we never would have picked that up
and we could have possibly transferred that embryo knowing that as a
three PN we would know that it’s unlikely, we know it's abnormal so we
wouldn't want to implant, and are unlikely to implant it, wouldn't want it
to because it's got too much DNA, it's abnormal. […] So although it might
not be saying this is your one embryo that needs to go back, it's telling us
which embryos to definitely not put back. So I think on the back of the
fact that it’s a good incubator and that is a benefit to some people I
would, I'd still preferentially use the time lapse over a benchtop, yeah.
(Head of embryology, Clinic E).
Here, the embryologist emphasises abnormal embryo development
events, such as direct cleavage where an embryo goes from 2 to 3 cells
too quickly (< 5 h) or the presence of three pronuclei (PN) instead of
the normal two. TLI has allowed professionals to deselect the embryos
which are of lower quality based on the observation of such events that
would normally be missed with standard incubation. Correlations be-
tween embryo behaviour and patient outcome are just now starting to
get research attention in the field, due to the availability of TLI.
TLI technologies, no doubt, offer embryologists more information
about embryos than was ever available. From a professional point of
view, it is difficult to argue that additional knowledge is not needed,
especially in a fast-changing field such as IVF. We observed that being
able to deselect embryos based on detected abnormal events was a
benefit that lab professionals stressed repeatedly. Conscious, however,
that this has not necessarily translated into RCT evidence of effective-
ness, interviewees talked about the unknown and underexplored po-
tential of TLI. For instance, TLI could reduce time to live birth by op-
timising the embryo selection process. One respondent, for example,
legitimised the use of TLI by highlighting the need for collective efforts
to develop knowledge in embryology:
Although there aren't these gold standard multi-centred randomised
control trials that show that time lapse is the best, it's a bit logical really
that you have an incubator that works as an incubator but also it can
capture images of embryos. It does no harm, we know it does no harm
but, it's because we don't know what to do with the information yet that
people are a bit, still a bit, there's camps, isn't there, people that don't
think that it’s worthwhile and it's very expensive. But I think that's down
to the lack of knowledge about what to do with the information because
we don't, we're getting all this information, what do we do with it, we just
need to work that out. (Head of embryology, Clinic B).
Professionals stressed that there might be extra steps required to
prove that TLI is worthwhile, but were hopeful that more information
can only be a positive aspect for both lab staff and patients. They also
talked about the benefit of knowledge production in order to counter
the evidence discourse. RCTs were often seen as lengthy and unfeasible.
Many professionals felt it would take an unbearably long time to
produce evidence of efficiency. This is, of course, not to say that the
intrinsic value of RCTs was not talked about. Most respondents did wish
to see more RCTs conducted on new IVF add-on treatments. However,
they had more nuanced ways to evaluate and legitimise the use of new
technologies, including the aforementioned benefits that they high-
lighted in the case of TLI. Given the low success rates and many un-
knowns in IVF treatment, TLI was described by respondents as a
knowledge production tool with great potential – even if that potential
is not fully apparent yet. While in its early days, TLI has been pro-
blematically portrayed in some marketing campaigns as an entirely AI-
powered selection tool, our research has found that it is rather seen as a
tool that gives professionals confidence in deselecting abnormal em-
bryos, thus narrowing the transfer pool. TLI also promises more
knowledge about embryos and their behaviour in the near future.
6.3. Managing patient hopes and expectations
The public conversation on add-ons and evidence has brought
concerns about commercialisation and patient vulnerability. The main
issue highlighted by the HFEA and other professional organisations is
that of fertility patients paying exorbitant sums of money for unproven
treatments. Although TLI is categorised as amber by the HFEA, meaning
that it shows some promise, there is currently no definitive evidence
that it improves LBRs. While professionals were indeed concerned
about commercialisation, they also talked about the dilemma of bal-
ancing patient hopes and expectations with institutional approaches to
evidence. Two respondents elaborated on the pressure to help patients
right now, while also trying to wait for more evidence to become
available:
The trouble with IVF is that there isn't many RCTs because no one wants
to go in an RCT, they [patients] want that improvement now. Patients
don't want to wait. They don't want to be a guinea pig in a trial, they just
want it now. So clinics are under pressure to introduce it straightaway,
they're under pressure to improve success rates, and I think that's fine if
you're not charging for it. (Embryologist, Clinic C).
Then some people might also say that when is this super quality RCT
going to come? Who is going to pay for it? It might take ten years before
this evidence comes out. So until then what are we supposed to do be-
cause the patient wants to get pregnant now. (Fertility consultant#2,
Clinic D).
There was a tension between the care responsibility that profes-
sionals felt towards patients and the public disapproval of add-ons. As
the respondents above mention, ‘patients don't want to wait,’ ‘they want
to get pregnant now’ and professionals want to do everything possible
to help them have a baby. The discourse of patient needs served as
further legitimation for the use of new treatments.
Respondents also understood that they need to manage patients'
expectations and deal with the promissory discourses that often sur-
round new technologies in IVF. This means that sometimes they might
offer emerging treatments, provided that risks and benefits are dis-
cussed thoroughly. As an embryologist from Clinic B put it, ‘if a patient
wants something and you can offer it to them and you counsel them for all of
the benefits and risks, then why wouldn't you give it to them.’ Some inter-
viewees talked about fertility care being very ‘patient driven’ where
patients might demand certain treatments they have researched online
or have heard of in the media. Consequently, NHS professionals
struggled with the idea of denying patients access to some treatments if
they could access them in a private clinic instead. Professionals who
worked in clinics offering TLI as part of their standard package and not
as an add-on felt that the technology should be offered routinely.
However, they also stressed that it is acceptable to offer TLI as an add-
on as long as patients are aware of the lack of evidence and make in-
formed choices.
Giving patients the ability to make informed decisions was seen by
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interviewees as the best way to guide treatment choices in light of the
limited evidence available. Fertility consultants (usually gynaecologists
specialised in reproductive medicine) and embryologists also valued the
ability to give patients more in-depth information obtained through
TLI. They emphasised that such technologies can build pathways to-
wards increasingly personalised treatment, as the following embryolo-
gist explained:
So we're a little bit more transparent and for patients that might help
them make a decision whether to have another cycle or if they have that
information and they're like could it be my eggs, could it be the sperm,
shall I use donor eggs next time, shall I use donor sperm. […] so it allows
us to give patients more information and kind of if embryos have done
kind of unusual things up until day three, we can kind of warn patients
that we might need to cancel the transfer on day five so it's, we use it to
kind of manage patient expectations as well. So I quite like it for that. I
don't ever want to go back. (Senior embryologist, Clinic E).
The interviewee stresses that TLI is beneficial for giving patients
more information about the source of their infertility, especially if they
struggle to get pregnant. Professionals are acutely aware that patients
want answers and see TLI as playing a role in deciding the best course of
treatment.
Overall, professionals felt very much constrained by the commer-
cialisation of the UK fertility sector. Their views on the use of EBM
guidelines in IVF reflect the ambiguous role that evidence currently
plays in their field. On one hand, institutional stakeholders decry the
lack of quality RCTs to prove treatment effectiveness. On the other
hand, care professionals have to juggle expectations and a commer-
cially driven innovation logic where technologies are often adopted
before enough evidence is available. TLI especially illustrates the dif-
ficulties they might face when evaluating new technologies and de-
ciding whether or not to offer them to patients. As we have stressed
here, evidence is not the only concern that drives clinical practice in
IVF. As a result, we suggest, in the discussion section, a more nuanced
approach to thinking about the role of evidence in fertility treatment.
7. Discussion
Despite the heated debate on the availability of evidence in support
of add-ons, the extended social science literature on IVF has overlooked
how professionals legitimise their current use of additional treatment in
their clinical practice. This paper helps fill this gap by examining the
legitimation narratives enacted by professionals and by focusing on
their understanding of evidence. Our findings show how individuals
deal with ambiguity when robust and definitive evidence is not avail-
able to support their clinical decision making. We extend previous
findings that healthcare staff have to rely on diverse forms of evidence
(Armstrong, 2002; Latimer et al., 2006; Rabeharisoa and Bourret, 2009;
Tonelli, 2006). Interestingly, in the case of fertility care, professionals
do not dispute orthodox EBM and do demand good quality RCTs to
prove the advantages of TLI. However, they simultaneously downplay
the role of hard evidence in understanding the benefits of TLI. As we
have shown, their negotiation of legitimacy focuses on three main
narratives: presenting TLI as an innovative piece of laboratory equip-
ment; highlighting its crucial role in the production of knowledge; and
the ability of these tools to offer additional information to manage
patient hopes and expectations.
Contrary to what emerged in studies of CAM, fertility professionals
do not engage with one of the three possible alternative strategies
identified (Borgerson, 2005), but seem to produce more articulated
legitimation narratives that include them all. They cosmetically accept
EBM standards and call for more RCTs, whilst relying on professional
experience and lower evidence to legitimise their use of TLI. At the
same time, they critically engage with EBM, downplaying the role of
evidence in the process of evaluating the worth of the tool. Although
there are some calls for a more inclusive approach to evidence (such as
in the case of CAM, see Trnka and Stöckelová, 2019), fertility profes-
sionals do not ultimately challenge the pyramid of evidence or the gold
standard of RCTs. Instead, they articulate their critiques of evidence
production in a more subtle way, using their professional expertise to
challenge the application of a pure EBM discourse to fertility treat-
ments.
Firstly, the emerging legitimation narratives question the prime
purpose of TLI, redefining its role in supporting clinical practice as a
sophisticated piece of lab equipment, rather than an add-on that in-
creases LBRs. Broadening the acceptable interpretation of what TLI is
and what it does allows them to focus on its multiple benefits and its
technical advantages (such as monitoring benefits, uninterrupted cul-
ture, data production). By refocusing their attention on the benefits of
TLI as support for laboratory work and tool for knowledge production
and patient support, fertility professionals effectively devalue the role
of hard evidence. This is due to EBM's inability to include multiple
perspectives on treatment benefits (for instance, the great support of-
fered by TLI to ‘deselect’ poor quality embryos and therefore reduce the
time to live birth). Thus, the case of TLI use in IVF further illustrates the
importance of care standards and the role professionals themselves play
in clinical decision-making (Kelly and Moore, 2012; Mykhalovskiy,
2003; Mykhalovskiy and Weir, 2004; Upshur, 2005). Professionals also
stress the tool's potential to develop the field of embryology itself, in
light of TLI's ability to provide a large amount of embryo development
data. Such information was not available in the past and can offer fu-
ture opportunities.
Secondly, through their legitimation narratives, fertility profes-
sionals redefine the notion of effectiveness (LBRs) as adopted by or-
thodox EBM. By stressing TLI benefits as a lab tool and emphasising its
potential, professionals challenge the dominant narrative that TLI is
only of value if it can improve LBRs. They focus instead on a more
holistic interpretation of potential benefits, where the ability of TLI to
provide more information for professionals and patients is highly va-
lued. Interestingly, the interpretation of LBRs as the only criterion of
success is shared across a variety of actors in the field as a response to
very different logics and interests. From an EBM and regulatory per-
spective, LBRs are the only outcome measure that allows objective
clinical performance comparisons. For patients and clinics, however,
success rates (expressed in pregnancy or delivery rates) are the easier
way to compare clinic performance. The stress on LBRs as the only
performance indicator has been highly criticised in the field (HFEA,
2019c) due to the measure's neglect of other relevant factors, including
the variation in patient populations. In addition, a focus on LBRs does
not account for clinical and individual decisions that influence the
outcome but cannot be made on the basis of clinical performance only.
For example, single embryo transfers are a safer option to avoid mul-
tiple pregnancies and related health risks, but reduce success rates.
Similarly, using donor eggs to treat older patients can dramatically
increase success rates, but has individual and moral implications.
Therefore, the focus with TLI on multiple uses and benefits is typical in
a field characterised by high uncertainty and moral and ethical issues.
As shown by other studies (Berg and Timmermans, 2000), we stress that
evidence cannot replace professional knowledge. Professional judgment
of TLI's value relies on a variety of knowledge forms (Armstrong, 2002),
including forms of medical expertise not based on EBM (Timmermans
and Berg, 2003).
Thirdly, our findings show how professional legitimation narratives
challenge the emerging notion of ‘add-on’ treatment itself (Heneghan
et al., 2016; HFEA, 2019b; Spencer et al., 2016). The current discourses,
focusing on the lack of effectiveness evidence for additional treatments,
have created a novel homogeneous category based on two main cri-
teria: their being an addition to the ‘standard’ IVF treatment; and their
cost. Focusing on laboratory work and practices, professionals offer a
situated understanding of TLI and differentiate it from other add-ons on
the basis of its varied advantages for clinical practice. Interviewees'
legitimation narratives imply a further critique of the current add-on
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discourse. Instead of asking if it is ethical to offer a treatment at an
additional cost where there is no evidence of LBR increases, profes-
sionals questioned whether it would actually be unethical not to offer
an available tool with potential (provided that patients are informed of
evidence and risks). Nonetheless, respondents acknowledge the ethical
dilemma of offering treatments to vulnerable patients, positioning it in
the broader context of a highly privatised sector.
8. Conclusion
To conclude, our findings show how fertility professionals are en-
acting, through the use of nuanced legitimation narratives, a novel form
of resistance to the orthodox EBM discourse that does not openly
challenge its rules or the concept of ‘hard evidence’. Rather, profes-
sional legitimation narratives question the premises of EBM and chal-
lenge the relevance of evidence, in a field still characterised by a high
level of uncertainty and very limited knowledge on the reproductive
process. The ability of TLI tools to answer previously inaccessible
questions without causing any harm is central to the optimistic en-
thusiasm for them. Although the case investigated is central in the
current debate on add-ons, due to the situated and specific nature of
TLI, further research is needed to explore whether similar dynamics
emerge in legitimation narratives of other treatments and devices.
Another limitation of this research is that it is not able to speak for
professionals working in private clinics where commercialisation plays
an even more important role in the choice of treatments offered to
patients. Nonetheless, our data demonstrates how the enactment of
professional legitimation narratives takes place in the public sector in
the UK. The way care professionals in the NHS conceptualise new
treatments can affect future policy directions and inequalities in ac-
cessing IVF treatments across the UK.
The case of TLI illustrates larger issues within IVF. Clinicians feel
pressure to improve outcomes immediately, given the commercial
nature of the industry. In addition, regulation in the UK focuses on EBM
to the extent where new technologies are not fully understood for all
the benefits they can offer. Such forces put NHS professionals in a
difficult position, especially given the lack of coordination and funding
for RCTs. In light of the data presented here, we suggest that, as an
emerging field, fertility care needs a more nuanced understanding of
the relationship between innovation and evidence.
Credit author statement
Manuela Perrotta: Conceptualization, Methodology, Investigation,
Writing - Original Draft, Writing - Review & Editing, Supervision,
Project administration, Funding acquisition. Alina Geampana:
Conceptualization, Methodology, Investigation, Formal analysis, Data
Curation, Writing - Original Draft, Writing - Review & Editing.
Acknowledgement
We are grateful to Stefan Timmermans, the senior editor who sup-
ported the revision process, and the anonymous reviewers whose con-
structive comments helped us to improve our contribution.
Financial support for this research was provided by the Wellcome
Trust, United Kingdom [108577/Z/15/Z].
Appendix A. List of Documents
The final document set assessed and approved by HRA Approval is listed below.
Document Version Date
Confirmation of any other Regulatory Approvals (e.g. NIGB) and all correspondence [Name of University Ethics approval for stage I] 30 November 2016
Confirmation of any other Regulatory Approvals (e.g. NIGB) and all correspondence [Name of University Ethics approval for stage II] 30 March 2017
Copies of advertisement materials for research participants [Call for participants] 1 06 April 2017
Covering letter on headed paper 19 May 2017
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) 15 July 2016
Interview schedules or topic guides for participants [Professionals] 1 20 March 2017
Interview schedules or topic guides for participants [Patients] 1 20 March 2017
Interview schedules or topic guides for participants [Focus group guide] 1 20 March 2017
IRAS Application Form [IRAS_Form] 24 May 2017
Laboratory Manual [Schedule of events] 09 May 2017
Letter from funder [Funding body - Acceptance letter] 24 September 2015
Letter from sponsor [Provisional Sponsorship letter] 19 May 2017
Other [Schedule of Events] 1 30 May 2017
Other [Statement of Activities] 1 30 May 2017
Other [CI Research Governance training] 04 April 2017
Other [Postdoc Research Governance training] 04 April 2017
Participant consent form [Interviews - patients] 1 09 May 2017
Participant consent form [Focus groups - professionals] 1 09 May 2017
Participant consent form [Focus groups - patients] 1 09 May 2017
Participant consent form [Sharing information] 1 09 May 2017
Participant consent form [Observations - professionals] 1 09 May 2017
Participant consent form [Observations - patients] 1 09 May 2017
Participant consent form [Interviews - professionals] 1 09 May 2017
Participant information sheet (PIS) [Observations - professionals] 1 09 May 2017
Participant information sheet (PIS) [Observations - patients ] 1 09 May 2017
Participant information sheet (PIS) [Interviews - professionals] 1 09 May 2017
Participant information sheet (PIS) [Interviews - patients] 1 09 May 2017
Participant information sheet (PIS) [Focus groups - professionals] 1 09 May 2017
Participant information sheet (PIS) [Focus groups - patients] 1 09 May 2017
Referee's report or other scientific critique report [Peer reviewers' comments on full project] 10 June 2015
Referee's report or other scientific critique report [Department support letter] 30 March 2015
Research protocol or project proposal [Research Protocol] 1 09 May 2017
Summary CV for Chief Investigator (CI) [PI - Short CV] 1 06 April 2017
Summary CV for student [Postdoc CV] 06 April 2017
Summary, synopsis or diagram (flowchart) of protocol in non technical language 1 09 May 2017
M. Perrotta and A. Geampana Social Science & Medicine 258 (2020) 113115
7
Appendix B. Summary of HRA Assessment
This appendix provides assurance to you, the sponsor and the NHS in England that the study, as reviewed for HRA Approval, is compliant with
relevant standards. It also provides information and clarification, where appropriate, to participating NHS organisations in England to assist in
assessing and arranging capacity and capability.
For information on how the sponsor should be working with participating NHS organisations in England, please refer to the, participating NHS
organisations, capacity and capability and Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment criteria)
sections in this appendix.
The following person is the sponsor contact for the purpose of addressing participating organisation questions relating to the study:
Name: Author One
Tel:
Email:
HRA assessment criteria
Section HRA Assessment Criteria Compliant with
Standards
Comments
1.1 IRAS application completed correctly Yes No comments
2.1 Participant information/consent documents and
consent process
Yes No comments
3.1 Protocol assessment Yes No comments
4.1 Allocation of responsibilities and rights are
agreed and documented
Yes A Statement of Activities and Schedule of Events have been provided for use with participating NHS
organisations in England. Exchange of the Statement of Activities will act as confirmation of capacity
and capability for an organisation to host the research.
4.2 Insurance/indemnity arrangements assessed Yes Insurance for the management and design of the study will be provided by the sponsor, and indemnity
for the conduct by the NHS.
Where applicable, independent contractors (e.g. General Practitioners) should ensure that the
professional indemnity provided by their medical defence organisation covers the activities expected
of them for this research study
4.3 Financial arrangements assessed Yes External study funding has been secured from the Funding Body. Funding is not available to
participating NHS organisations.
5.1 Compliance with the Data Protection Act and
data security issues assessed
Yes No comments
5.2 CTIMPS Arrangements for compliance with the
Clinical Trials Regulations assessed
Not Applicable No comments
5.3 Compliance with any applicable laws or regula-
tions
Yes No comments
6.1 NHS Research Ethics
Committee favourable opinion received for ap-
plicable studies
Yes The study has a favourable ethical opinion from the XXX Research Ethics Committee.
6.2 CTIMPS Clinical Trials Authorisation (CTA)
letter received
Not Applicable No comments
6.3 Devices MHRA notice of no objection received Not Applicable No comments
6.4 Other regulatory approvals and authorisations
received
Not Applicable No comments
Appendix C. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.socscimed.2020.113115.
References
Armstrong, D., 2002. Clinical autonomy, individual and collective: the problem of
changing doctors' behaviour. Soc. Sci. Med. 55 (10), 1771–1777.
Armstrong, D., 2007. Professionalism, indeterminacy and the EBM project. BioSocieties 2
(1), 73–84.
Armstrong, S., Arroll, N., Cree, L.M., Jordan, V., Farquhar, C., 2015. Time‐lapse systems
for embryo incubation and assessment in assisted reproduction. Cochrane Database
Syst. Rev.(2).
Armstrong, S., Bhide, P., Jordan, V., Pacey, A., Marjoribanks, J., Farquhar, C., 2019.
Time‐lapse systems for embryo incubation and assessment in assisted reproduction.
Cochrane Database Syst. Rev.(5).
Baer, H.A., 2006. The drive for legitimation in Australian naturopathy: successes and
dilemmas. Soc. Sci. Med. 63 (7), 1771–1783.
Berg, M., Timmermans, S., 2000. Orders and their others: on the constitution of uni-
versalities in medical work. Configurations 8 (1) 3 1-6.
Bhandari, M., Montori, V., Devereaux, P.J., Dosanjh, S., Sprague, S., Guyatt, G.H., 2003.
Challenges to the practice of evidence-based medicine during residents' surgical
training: a qualitative study using grounded theory. Acad. Med. 78 (11), 1183–1190.
Borgerson, K., 2005. Evidence-based alternative medicine? Perspect. Biol. Med. 48 (4),
502–515.
Concato, J., Shah, N., Horwitz, R.I., 2000. Randomized, controlled trials, observational
studies, and the hierarchy of research designs. N. Engl. J. Med. 342 (25), 1887–1892.
De Vries, R., Lemmens, T., 2006. The social and cultural shaping of medical evidence:
case studies from pharmaceutical research and obstetric science. Soc. Sci. Med. 62
(11), 2694–2706.
Deaton, A., Cartwright, N., 2018. Understanding and misunderstanding randomized
controlled trials. Soc. Sci. Med. 210, 2–21.
Degele, N., 2005. On the margins of everything: doing, performing, and staging science in
homeopathy. Sci. Technol. Hum. Val. 30 (1), 111–136.
Derkatch, C., 2016. Bounding Biomedicine: Evidence and Rhetoric in the New Science of
Alternative Medicine. University of Chicago Press.
Devereaux, P.J., Yusuf, S., 2003. The evolution of the randomized controlled trial and its
M. Perrotta and A. Geampana Social Science & Medicine 258 (2020) 113115
8
role in evidence‐based decision making. J. Intern. Med. 254 (2), 105–113.
Dhont, M., 2013. Evidence-based reproductive medicine: a critical appraisal. Facts, Views
Vision ObGyn 5 (3), 233.
Feinstein, A.R., 1994. Clinical judgment revisited: the distraction of quantitative models.
Ann. Intern. Med. 120 (9), 799–805.
Feinstein, A.R., Horwitz, R.I., 1997. Problems in the “evidence” of “evidence-based
medicine”. Am. J. Med. 103 (6), 529–535.
Foley, L., Faircloth, C.A., 2003. Medicine as discursive resource: legitimation in the work
narratives of midwives. Sociol. Health Illness 25 (2), 165–184.
Fontanarosa, P.B., Lundberg, G.D., 1998. Alternative medicine meets science. J. Am. Med.
Assoc. 280 (18), 1618.
Gibson, W.J., 2018. Homeopathy, Western medicine and the discourse of evidence: ne-
gotiating legitimacy in a public online forum. Curr. Sociol. 66 (7), 1013–1030.
Glaser, B.G., Strauss, A.L., 2017. Discovery of Grounded Theory: Strategies for Qualitative
Research. Routledge.
Goldenberg, M.J., 2006. On evidence and evidence-based medicine: lessons from the
philosophy of science. Soc. Sci. Med. 62 (11), 2621–2632.
Greenhalgh, T., 2014. How to Read a Paper: the Basics of Evidence-Based Medicine. John
Wiley & Sons.
Gubrium, J.F., Holstein, J.A., 1997. The New Language of Qualitative Method. Oxford
University Press on Demand.
Hansen, K., Kappel, K., 2012. Pre-trial beliefs in complementary and alternative medicine:
whose pre-trial belief should be considered? Med. Healthc. Philos. 15 (1), 15–21.
Harper, J., Jackson, E., Sermon, K., Aitken, R.J., Harbottle, S., Mocanu, E., et al., 2017.
Adjuncts in the IVF laboratory: where is the evidence for ‘add-on’interventions? Hum.
Reprod. 32 (3), 485–491.
Heneghan, C., Spencer, E.A., Bobrovitz, N., Collins, D.R.J., Nunan, D., Plüddemann, A.,
et al., 2016. Lack of evidence for interventions offered in UK fertility centres. BMJ
355, i6295.
The Human Fertility and Embryology Authority, 2018. Fertility Treatment 2014-2016:
Trends and Figures. Retrieved at. https://www.hfea.gov.uk/media/2563/hfea-
fertility-trends-and-figures-2017-v2.pdf.
The Human Fertility and Embryology Authority, 2019. Fertility Treatment 2017: Trends
and Figures. Retrieved at. https://www.hfea.gov.uk/media/2894/fertility-
treatment-2017-trends-and-figures-may-2019.pdf.
The Human Fertility and Embryology Authority, 2019. Treatment Add-Ons. Retrieved at.
https://www.hfea.gov.uk/treatments/explore-all-treatments/treatment-add-ons/.
The Human Fertility and Embryology Authority, 2019. Choose a Fertility Clinic.
Retrieved at. https://www.hfea.gov.uk/choose-a-clinic/.
Holstein, J.A., Gubrium, J.F., 2000. The Self We Live by: Narrative Identity in a
Postmodern World.
Hughes, D., Doheny, S., 2019. Doing evidence-based medicine? How NHS managers ra-
tion high-cost drugs. Soc. Sci. Med.
Hurley, R., 2013. Are new technologies in infertility treatment always good news? BMJ
347, f6004.
Jackson, S., Scambler, G., 2007. Perceptions of evidence‐based medicine: traditional
acupuncturists in the UK and resistance to biomedical modes of evaluation. Sociol.
Health Illness 29 (3), 412–429.
Kelly, M.P., Moore, T.A., 2012. The judgement process in evidence-based medicine and
health technology assessment. Soc. Theor. Health 10 (1), 1–19.
Kirmayer, L.J., 2012. Cultural competence and evidence-based practice in mental health:
epistemic communities and the politics of pluralism. Soc. Sci. Med. 75 (2), 249–256.
Kristiansen, I.S., Mooney, G. (Eds.), 2004. Evidence-based Medicine: in its Place, vol. 3
Routledge.
Lambert, H., 2006. Accounting for EBM: notions of evidence in medicine. Soc. Sci. Med.
62 (11), 2633–2645.
Lambert, H., 2012. Medical pluralism and medical marginality: bone doctors and the
selective legitimation of therapeutic expertise in India. Soc. Sci. Med. 74 (7),
1029–1036.
Latimer, J., Featherstone, K., Atkinson, P., Clarke, A., Pilz, D.T., Shaw, A., 2006.
Rebirthing the clinic: the interaction of clinical judgment and genetic technology in
the production of medical science. Sci. Technol. Hum. Val. 31 (5), 599–630.
Macklon, N.S., Ahuja, K.K., Fauser, B.C.J.M., 2019. Building an evidence base for IVF
‘add-ons’. Reprod. Biomed. Online 38 (6), 853–856.
Miles, A., Bentley, P., Polychronis, A., Grey, J., 1997. Evidence‐based medicine: why all
the fuss? This is why. J. Eval. Clin. Pract. 3 (2), 83–86.
Moreira, T., 2007. Entangled evidence: knowledge making in systematic reviews in
healthcare. Sociol. Health Illness 29 (2), 180–197.
Morreim, E.H., 2003. A dose of our own medicine: alternative medicine, conventional
medicine, and the standards of science. J. Law Med. Ethics 31 (2), 222–235.
Mowat, R., Subramanian, S.V., Kawachi, I., 2018. Randomized controlled trials and evi-
dence-based policy: a multidisciplinary dialogue. Soc. Sci. Med (1982), 210, 1.
Murad, M.H., Asi, N., Alsawas, M., Alahdab, F., 2016. New evidence pyramid. BMJ
Evidence Based Med. 21 (4), 125–127.
Mykhalovskiy, E., 2003. Evidence-based medicine: ambivalent reading and the clinical
recontextualization of science. Health 7 (3), 331–352.
Mykhalovskiy, E., Weir, L., 2004. The problem of evidence-based medicine: directions for
social science. Soc. Sci. Med. 59 (5), 1059–1069.
Pope, C., 2003. Resisting evidence: the study of evidence-based medicine as a con-
temporary social movement. Health 7 (3), 267–282.
Rabeharisoa, V., Bourret, P., 2009. Staging and weighting evidence in biomedicine:
comparing clinical practices in cancer genetics and psychiatric genetics. Soc. Stud.
Sci. 39 (5), 691–715.
Repping, S., 2019. Evidence-based medicine and infertility treatment. Lancet 393
(10170), 380–382.
Rutherford, A.J., 2017. Should the HFEA be regulating the add‐on treatments for IVF/ICSI
in the UK? for: regulation of the fertility add‐on treatments for IVF. BJOG An Int. J.
Obstet. Gynaecol. 124 (12) 1848-1848.
Spencer, E.A., Mahtani, K.R., Goldacre, B., Heneghan, C., 2016. Claims for fertility in-
terventions: a systematic assessment of statements on UK fertility centre websites.
BMJ Open 6 (11), e013940.
Stocking, K., Wilkinson, J., Lensen, S., Brison, D.R., Roberts, S.A., Vail, A., 2019. Are
interventions in reproductive medicine assessed for plausible and clinically relevant
effects? A systematic review of power and precision in trials and meta-analyses. Hum.
Reprod. 34 (4), 659–665.
Tausig, M., Subedi, S., 1997. The modern mental health system in Nepal: organizational
persistence in the absence of legitimating myths. Soc. Sci. Med. 45 (3), 441–447.
Timmermans, S., Berg, M., 2003. The Gold Standard: the Challenge of Evidence-Based
Medicine and Standardization in Health Care. Temple University Press,
Philadelphia, PA.
Tonelli, M.R., 2006. Integrating evidence into clinical practice: an alternative to evi-
dence‐based approaches. J. Eval. Clin. Pract. 12 (3), 248–256.
Traynor, M., 2009. Indeterminacy and technicality revisited: how medicine and nursing
have responded to the evidence based movement. Sociol. Health Illness 31 (4),
494–507.
Trnka, S., Stöckelová, T., 2019. Equality, efficiency and effectiveness: going beyond RCTs
in AL Cochrane's vision of health care. Sociol. Health Illness 41 (2), 234–248.
Upshur, R., 2005. Looking for rules in a world of exceptions: reflections on evidence-
based practice. Perspect. Biol. Med. 48 (4), 477–489.
Wilkinson, J., Vail, A., Roberts, S.A., 2017. Direct-to-consumer advertising of success
rates for medically assisted reproduction: a review of national clinic websites. BMJ
Open 7 (1), e012218.
Wilkinson, J., Bhattacharya, S., Duffy, J.M.N., Kamath, M.S., Marjoribanks, J., Repping,
S., et al., 2019. Reproductive medicine: still more ART than science? BJOG An Int. J.
Obstet. Gynaecol. 126 (2), 138–141.
Wodak, R., Meyer, M. (Eds.), 2015. Methods of Critical Discourse Studies. Sage.
M. Perrotta and A. Geampana Social Science & Medicine 258 (2020) 113115
9
